Minimally Invasive Techniques in Quest of Holy Grail of Surgical Management of Enlarged Prostates: a Narrative Review

Overview

Journal World J Urol

Specialty Urology

Date 2024 Jan 13

PMID 38217727

Authors

Joao G Porto

Renil Titus

Feres Camargo

Ansh Bhatia

Nehizena Ahie

Ruben Blachman-Braun

Ankur Malpani

Diana M Lopategui

Thomas R W Herrmann

Robert Marcovich

Hemendra N Shah

Affiliations

Soon will be listed here.

Abstract

Purpose: Past decade has seen a renewed interest in minimally invasive surgical techniques (MISTs) for management of enlarged prostate. This narrative review aims to explore newer MIST for benign prostatic hyperplasia (BPH) which are not yet integrated into established societal guidelines.

Methods: We conducted a literature search across PubMed, Google Scholar, and FDA ClinicalTrials.gov databases on June 1st, 2023, to identify studies published within the past decade exploring various MISTs for BPH. Additionally, we gathered insights from abstracts presented in meetings of professional associations and corporate websites. We broadly classified these procedures into three distinct categories: energy-based, balloon dilation, and implant/stent treatments. We collected detail information about the device, procedure details, its inclusion and exclusion criteria, and outcome.

Results: Our review reveals that newer energy-based MISTs include Transperineal Laser Ablation, Transurethral Ultrasound Ablation, and High-Intensity Focused Ultrasound. In the sphere of balloon dilation, Transurethral Columnar Balloon Dilation and the Optilume BPH Catheter System were gaining momentum. The noteworthy implants/stents that are on horizon include Butterfly Prostatic Retraction Device, Urocross Expander System, Zenflow Spring System, and ProVee Urethral Expander System.

Conclusion: The exploration of various MISTs reflects ongoing efforts to enhance patient care and address limitations of existing treatments. This review provides a bird-eye view and valuable insights for urologists and researchers seeking to navigate the dynamic landscape of MISTs in the quest for effective and minimally invasive solutions for enlarged prostates.

Citing Articles

Anatomic and Clinical Effects of Focal Laser Ablation of the Prostate on Symptomatic Benign Prostatic Hyperplasia.

Walser E, Zimmerer R, Nance A, Masood I, Saleem A Cancers (Basel). 2025; 17(3).

PMID: 39941842 PMC: 11816294. DOI: 10.3390/cancers17030475.

The Optilume BPH Catheter System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Kaur P, Saini S Transl Androl Urol. 2024; 13(6):1071-1073.

PMID: 38983480 PMC: 11228686. DOI: 10.21037/tau-23-673.

References

Strebel R, Kaplan S . The state of TURP through a historical lens. World J Urol. 2021; 39(7):2255-2262. DOI: 10.1007/s00345-021-03607-7. View

Lerner L, McVary K, Barry M, Bixler B, Dahm P, Das A . Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. J Urol. 2021; 206(4):806-817. DOI: 10.1097/JU.0000000000002183. View

Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D . New Ultra-minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia: A Systematic Review and Analysis of Comparative Outcomes. Eur Urol Open Sci. 2021; 33:28-41. PMC: 8473553. DOI: 10.1016/j.euros.2021.08.009. View

Elterman D, Zorn K, Chughtai B, Bhojani N . Is it time to offer True Minimally Invasive Treatments (TMIST) for BPH? - A review of office-based therapies and introduction of a new technology category. Can J Urol. 2021; 28(2):10580-10583. View

Kuo H . Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia. Urol Int. 1998; 60(2):85-91. DOI: 10.1159/000030217. View

McVary K, Gittelman M, Goldberg K, Patel K, Shore N, Levin R . Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021; 206(3):715-724. DOI: 10.1097/JU.0000000000001778. View

Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn K . Large, Multi-Center, Prospective Registry of Rezūm Water Vapor Therapy for Benign Prostatic Hyperplasia. Urology. 2022; 165:261-267. DOI: 10.1016/j.urology.2022.02.001. View

Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella C . Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study. Cardiovasc Intervent Radiol. 2017; 40(9):1440-1446. DOI: 10.1007/s00270-017-1662-9. View

van Riel L, van Kollenburg R, Vis A, van Leeuwen P, de Reijke T, de Bruin D . Safety and Feasibility of Soractelite Transperineal Focal Laser Ablation for Prostate Cancer and Short-term Quality of Life Analysis from a Multicenter Pilot Study. Eur Urol Open Sci. 2022; 39:48-54. PMC: 9068724. DOI: 10.1016/j.euros.2022.02.012. View

10.

DE Rienzo G, Lorusso A, Minafra P, Zingarelli M, Papapicco G, Lucarelli G . Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol. 2020; 80(1):95-103. DOI: 10.1016/j.eururo.2020.08.018. View

11.

Manenti G, Perretta T, Calcagni A, Ferrari D, Ryan C, Fraioli F . 3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia. Eur Radiol Exp. 2021; 5(1):41. PMC: 8445741. DOI: 10.1186/s41747-021-00239-9. View

12.

Cai H, Fang J, Kong F, Xu C, Chen C, Wang W . Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy. Acta Radiol. 2021; 63(4):553-558. DOI: 10.1177/02841851211003289. View

13.

Bertolo R, Iacovelli V, Cipriani C, Carilli M, Vittori M, Antonucci M . Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: a randomized trial. BJU Int. 2023; 132(1):100-108. DOI: 10.1111/bju.16008. View

14.

Cai H, Zhu C, Fang J . Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: two similar short-term efficacies. Acta Radiol. 2022; 64(5):2033-2039. DOI: 10.1177/02841851221140214. View

15.

Klotz L, Pavlovich C, Chin J, Hatiboglu G, Koch M, Penson D . Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2020; 205(3):769-779. DOI: 10.1097/JU.0000000000001362. View

16.

Viitala A, Anttinen M, Wright C, Virtanen I, Makela P, Hovinen T . Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. BJU Int. 2021; 129(2):208-216. DOI: 10.1111/bju.15523. View

17.

Bihrle R, Foster R, Sanghvi N, Fry F, Donohue J . High-intensity focused ultrasound in the treatment of prostatic tissue. Urology. 1994; 43(2 Suppl):21-6. DOI: 10.1016/0090-4295(94)90214-3. View

18.

Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M . Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol. 2000; 37(6):687-94. DOI: 10.1159/000020219. View

19.

Nahar B, Bhat A, Reis I, Soodana-Prakash N, Becerra M, Lopategui D . Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol. 2020; 204(3):483-489. DOI: 10.1097/JU.0000000000001015. View

20.

Abreu A, Peretsman S, Iwata A, Shakir A, Iwata T, Brooks J . High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series. J Urol. 2020; 204(4):741-747. DOI: 10.1097/JU.0000000000001126. View